Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination

  • Lee, Sung Uk (The Proton Therapy Center, Research Institute and Hospital, National Cancer Center) ;
  • Cho, Kwan Ho (The Proton Therapy Center, Research Institute and Hospital, National Cancer Center)
  • Received : 2017.06.14
  • Accepted : 2017.08.11
  • Published : 2017.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Locally advanced prostate cancer (LAPC) is defined as histologically proven T3-4 prostatic adenocarcinoma. In this review, we define the individual roles of radiotherapy (RT), short-term (ST-) and long-term (LT-) androgen deprivation therapy (ADT), and their combination in multimodal therapy for LAPC. Despite limitations in comparing the clinical outcomes among published papers, in the present study, a trend of 10-year clinical outcomes was roughly estimated by calculating the average rates weighted by the cohort number. With RT alone, the following rates were estimated: 87% biochemical failure, 34% local failure (LF), 48% distant metastasis (DM), 38% overall survival (OS), and 27% disease-specific mortality (DSM). Those associated with ADT alone were 74% BCF, 54% OS, and 25% DSM, which appeared to be better than those of RT alone. The addition of ADT to RT produced a notable local and systemic effect, regardless of ST- or LT-ADT. The LF rate decreased from 34% with RT alone to 21% with ST-ADT and further to 15% with LT-ADT. The DM and DSM rates also showed a similar trend among RT alone, RT+ST-ADT, and RT+LT-ADT. The combination of RT+LT-ADT resulted in the best long-term clinical outcomes, indicating that both RT and ADT are important parts of multimodal therapy.

Keywords

References

  1. Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet 2016;387:70-82. https://doi.org/10.1016/S0140-6736(14)61947-4
  2. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int 2013;1:47-58. https://doi.org/10.12954/PI.12014
  3. Oh CM, Won YJ, Jung KW, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013. Cancer Res Treat 2016;48:436-50. https://doi.org/10.4143/crt.2016.089
  4. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90. https://doi.org/10.1016/j.ijrobp.2004.08.047
  5. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-73. https://doi.org/10.1016/S1470-2045(10)70223-0
  6. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46. https://doi.org/10.1016/S0360-3016(00)01516-9
  7. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21. https://doi.org/10.1200/JCO.1997.15.3.1013
  8. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52. https://doi.org/10.1016/S0360-3016(01)01579-6
  9. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585-91. https://doi.org/10.1200/JCO.2007.13.9881
  10. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6. https://doi.org/10.1016/S0140-6736(02)09408-4
  11. McLaughlin PW, Liss AL, Nguyen PL, et al. ACR Appropriateness Criteria locally advanced, high-risk prostate cancer. Am J Clin Oncol 2017;40:1-10. https://doi.org/10.1097/COC.0000000000000354
  12. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104-11. https://doi.org/10.1016/S0140-6736(11)61095-7
  13. Mason MD, Parulekar WR, Sydes MR, et al. Final report of the intergroup randomized study of combined androgendeprivation therapy plus radiotherapy versus androgendeprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015;33:2143-50. https://doi.org/10.1200/JCO.2014.57.7510
  14. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8. https://doi.org/10.1016/S0140-6736(08)61815-2
  15. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8. https://doi.org/10.1200/JCO.2003.11.023
  16. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504. https://doi.org/10.1200/JCO.2007.14.9021
  17. Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008;53:1172-9. https://doi.org/10.1016/j.eururo.2007.12.030
  18. Brundage M, Sydes MR, Parulekar WR, et al. Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-oflife outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. J Clin Oncol 2015;33:2151-7. https://doi.org/10.1200/JCO.2014.57.8724
  19. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. https://doi.org/10.1016/j.ijrobp.2007.06.054
  20. Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056-63. https://doi.org/10.1016/j.ijrobp.2010.03.049
  21. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. https://doi.org/10.1001/jama.294.10.1233
  22. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, noninferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-60. https://doi.org/10.1016/S1470-2045(16)30102-4
  23. Lee WR, Dignam JJ, Amin MB, et al. Randomized phase iii noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016;34:2325-32. https://doi.org/10.1200/JCO.2016.67.0448
  24. Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:275-85. https://doi.org/10.1016/j.ijrobp.2016.11.026
  25. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a doseescalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:286-95. https://doi.org/10.1016/j.ijrobp.2017.01.008
  26. Rodda S, Morris WJ, Hamm J, Duncan G. ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with doseescalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:581-9. https://doi.org/10.1016/j.ijrobp.2017.02.027
  27. James N, Mason M. Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: first survival results from STAMPEDE [abstract]. J Clin Oncol 2015;33(Suppl):5001.
  28. Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521) [abstract]. J Clin Oncol 2015;33(Suppl):LBA5002. https://doi.org/10.1200/jco.2015.33.18_suppl.lba5002
  29. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60. https://doi.org/10.1056/NEJMoa1704174

Cited by

  1. Yes or no to local therapy for oligometastatic prostate cancer? vol.15, pp.7, 2018, https://doi.org/10.1038/s41585-018-0028-7
  2. Association between decreased expression of estrogen receptor alpha, androgen receptor and phosphatase and tensin homolog immunoexpression in the canine prostate vol.39, pp.1, 2017, https://doi.org/10.1590/1678-5150-pvb-5699
  3. Identification of prognostic biomarkers of prostate cancer with long non-coding RNA-mediated competitive endogenous RNA network vol.17, pp.4, 2017, https://doi.org/10.3892/etm.2019.7277
  4. Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions vol.26, pp.8, 2021, https://doi.org/10.3390/molecules26082228
  5. Feasibility of Synthetic Computed Tomography Images Generated from Magnetic Resonance Imaging Scans Using Various Deep Learning Methods in the Planning of Radiation Therapy for Prostate Cancer vol.14, pp.1, 2022, https://doi.org/10.3390/cancers14010040